Company
Ypsilon Therapeutics
Develops TCRm antibodies and T-cell engagers that target solid tumors while sparing healthy tissue.
Also known as Alloy Therapeutics, Inc.
- Business model
- B2B
- Legal name
- Alloy Therapeutics, Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
Ypsilon Therapeutics develops next-generation cancer therapies: T-cell receptor mimic (TCRm) antibodies and bispecific T-cell engagers (TCEs) that selectively target and destroy solid tumors (e.g., triple-negative breast and non-small-cell lung cancer) while sparing healthy tissue.
Loading relationship preview